{"pmid":32426207,"pmcid":"PMC7228884","title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series.","text":["COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series.","Mult Scler Relat Disord","Hughes, Richard","Pedotti, Rosetta","Koendgen, Harold","32426207"],"journal":"Mult Scler Relat Disord","authors":["Hughes, Richard","Pedotti, Rosetta","Koendgen, Harold"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426207","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.msard.2020.102192","e_drugs":["ocrelizumab"],"topics":["Diagnosis"],"weight":1,"_version_":1667252837959073792,"score":9.490897,"similar":[{"pmid":32426210,"pmcid":"PMC7227515","title":"Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.","text":["Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.","Mult Scler Relat Disord","Suwanwongse, Kulachanya","Shabarek, Nehad","32426210"],"journal":"Mult Scler Relat Disord","authors":["Suwanwongse, Kulachanya","Shabarek, Nehad"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426210","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.msard.2020.102201","e_drugs":["ocrelizumab"],"topics":["Case Report"],"weight":1,"_version_":1667252837985288193,"score":62.613716},{"pmid":32480327,"title":"Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.","text":["Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.","Mult Scler Relat Disord","Suwanwongse, Kulachanya","Shabarek, Nehad","32480327"],"journal":"Mult Scler Relat Disord","authors":["Suwanwongse, Kulachanya","Shabarek, Nehad"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480327","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.msard.2020.102201","topics":["Case Report"],"weight":1,"_version_":1668437835157340160,"score":62.613716},{"pmid":32464586,"title":"Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.","text":["Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.","Mult Scler Relat Disord","Ghajarzadeh, Mahsa","Mirmosayyeb, Omid","Barzegar, Mahdi","Nehzat, Nasim","Vaheb, Saeed","Shaygannejad, Vahid","Maghzi, Amir-Hadi","32464586"],"journal":"Mult Scler Relat Disord","authors":["Ghajarzadeh, Mahsa","Mirmosayyeb, Omid","Barzegar, Mahdi","Nehzat, Nasim","Vaheb, Saeed","Shaygannejad, Vahid","Maghzi, Amir-Hadi"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464586","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.msard.2020.102222","keywords":["covid-19","multiple sclerosis","ocrelizumab"],"topics":["Case Report"],"weight":1,"_version_":1668079521483456513,"score":48.989178}]}